This article is more than 5 years old. Information may no longer be current.
Cardiology Today's Intervention Top 5 articles posted in February
Cardiology Today’s Intervention compiled a list of the top 5 stories posted to Healio.com/Intervention in February.
This month Cardiology Today’s Intervention’s readers were most interested in type 2 MI in patients undergoing angiography, the effects of treatment with newer oral anticoagulants compared with warfarin in patients with venous thromboembolism, the FDA approval of the first balloon-expandable stent graft for use in iliac artery, the de novo classification for embolic protection device for prevention of stroke during transcatheter aortic valve replacement, the future of bariatric embolization and metabolic interventions, and much more.
Type 2 MI common, associated with poor outcomes in patients undergoing angiography
More than 12% of a cohort of patients undergoing PCI or peripheral artery angiography had type 2 MI, and it was often recurrent, according to results from the CASABLANCA study.
Evidence on safety, efficacy of newer oral anticoagulants in patients with VTE continues to mount
HOLLYWOOD, Fla. — In patients with venous thromboembolism, treatment with non-vitamin K oral anticoagulants is safer than warfarin without compromising efficacy, according to a speaker at the International Symposium on Endovascular Therapy.
First balloon-expandable stent graft for use in iliac artery approved by FDA
W.L. Gore and Associates announced the FDA approval of the first balloon-expandable stent graft for use in treatment of de novo or restenotic lesions in the iliac artery.
FDA panel: More data needed for embolic protection device for TAVR procedures
The FDA’s Circulatory System Devices Panel said despite flaws in current data, de novo classification may be warranted for an embolic protection device for prevention of stroke during TAVR procedures.
Expert discusses potential of bariatric embolization, metabolic interventions
HOLLYWOOD, Fla. — Bariatric embolization and metabolic interventions may be the “next revolution” in endovascular medicine, according to a speaker at the International Symposium on Endovascular Therapy.